Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Pier Luigi Zinzani, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, José S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, DMed Sci, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139416

Published: 2020

Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142565

Published: 2020

Journal Articles

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142871

Published: 2020

Journal Articles

Three-Dimensional Telomere Analysis Using Teloview® Technology Predicts the Response of Classic Hodgkin's Lymphoma Patients to First Line Therapy at Point of Diagnosis

Sherif Louis, PhD BSc, MSc, Nathalie A Johnson, MD PhD, Pierre Brousset, MD PhD, Olga Ludkovski, MSc, Yulia Shifrin, PhD, Sabine Mai, PhD, Hans Knecht, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140624

Published: 2020

Journal Articles

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

Samantha Worme, BSc, Selin Jessa, BSc, William Poon, BSc, Maja Jankovic, MSc, Gabriela Galicia Vazquez, PhD, Alexandre Bazinet, MD, Katharine Fooks, BSc, Isabella Iasenza, BSc, Patricia Arreba-Tutusaus, PhD, Kolja Eppert, PhD, Ioannis Ragoussis, PhD, Yu Chang Wang, PhD, Nathalie A Johnson, MD PhD, Sarit E Assouline, MD MSc, Claudia L Kleinman, PhD, François E Mercier, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143221

Published: 2020

Journal Articles

Apoptotic Blocks in Primary Non-Hodgkin B-Cell Lymphomas Identified By BH3 Profiling

Nathalie A Johnson, MD PhD, Claudia M Wever, PhD, Dominique Geoffrion, BSc, Ghassemian Artin, MD, Brailovski Eugene, Pierre Sesques, MD, Jeremy A. Ryan, SM, Liliana Stoica, Josee Hebert, MD, Tina Petrogiannis-Haliotis, MD PhD, Svetlana Dmitrienko, MD PhD, Frenkiel Saul, MD, German Ott, MD, Annette Staiger, Christian Steidl, MD, David W. Scott, PhD MD, FRACP, FRCPA, Koren Kathleen Mann, PhD, Anthony Letai, MD PhD

Blood (2018) 132 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2018-99-118225

Published: 2018

Journal Articles

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, MD, Robert W. Chen, MD, Hun Ju Lee, MD, Philippe Armand, MD PhD, Nathalie A Johnson, MD PhD, Pauline Brice, MD, John Radford, MD FRCP, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian Von Tresckow, MD, Margaret A. Shipp, MD, Eunhee Kim, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2018) 132 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2018-99-117045

Published: 2018

Journal Articles

Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP

Blood (2010) 116 (21): 2005.

https://doi.org/10.1182/blood.V116.21.2005.2005

Published: 2010

Journal Articles

Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets

Blood (2010) 116 (21): 632.

https://doi.org/10.1182/blood.V116.21.632.632

Published: 2010

Journal Articles

Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing

Blood (2010) 116 (21): 804.

https://doi.org/10.1182/blood.V116.21.804.804

Published: 2010

Journal Articles

BCL2 Is Highly Mutated In Diffuse Large B-Cell Lymphoma

Johanna M Schuetz, Nathalie A Johnson, MD, Ph.D., Ryan D Morin, M.Sc., Martin Hirst, Ph.D., Yongjun Zhao, M.Sc., DVM, Angela Tam, B.Sc., Richard Moore, Ph.D., Thomas Zeng, M.Sc., Marco A Marra, Ph.D., Joseph M. Connors, MD, Angela R Brooks-Wilson, Randy D. Gascoyne, MD

Blood (2010) 116 (21): 4187.

https://doi.org/10.1182/blood.V116.21.4187.4187

Published: 2010

Journal Articles

Mutations In MLL2 and MEF2B Genes In Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Blood (2010) 116 (21): 473.

https://doi.org/10.1182/blood.V116.21.473.473

Published: 2010

Journal Articles

MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.

Blood (2009) 114 (22): 1100.

https://doi.org/10.1182/blood.V114.22.1100.1100

Published: 2009

Journal Articles

FAS Mutations in Follicular Lymphoma Are Rare but Associated with Aggressive Clinical Behavior.

Nathalie A. Johnson, MD, Ryan Morin, PhD, Tesa Severson, M.Sc., Andrew J. Mungall, Ph.D., Yongjun Zhao, Jacqueline E. Schein, M.Sc., Merrill Boyle, Bruce Woolcock, PhD, Richard Moore, Ph.D., Robert Holt, Douglas E. Horsman, Joseph M. Connors, Steven Jones, Martin Hirst, Marco A Marra, Randy D. Gascoyne, MD

Blood (2009) 114 (22): 3967.

https://doi.org/10.1182/blood.V114.22.3967.3967

Published: 2009

Journal Articles

Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner

Nathalie A Johnson, MD, Kerry J. Savage, MD, Susanna Ben-Neriah, Christian Steidl, MD, Richard Klasa, MD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Douglas E. Horsman, MD

Blood (2008) 112 (11): 804.

https://doi.org/10.1182/blood.V112.11.804.804

Published: 2008

Journal Articles

Paraffin-Based 6-Gene Model Predicts Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.

Raquel Malumbres, PhD, Nathalie A. Johnson, MD, Laurie H. Sehn, MD, Yaso Natkunam, MD, Rob Tibshirani, PhD, Javier Briones, MD, Joseph M. Connors, MD, Ronald Levy, MD, Randy D. Gascoyne, MD, Izidore S. Lossos, MD

Blood (2007) 110 (11): 49.

https://doi.org/10.1182/blood.V110.11.49.49

Published: 2007

Journal Articles

Insights into Disease Evolution of Transformed Follicular Lymphoma Derived from Cytogenetics.

Nathalie A. Johnson, MD, Abdul Al-Tourah, MD, Douglas E. Horsman, MD, Joseph M. Connors, MD, Randy D. Gascoyne, MD

Blood (2005) 106 (11): 604.

https://doi.org/10.1182/blood.V106.11.604.604

Published: 2005

NARROW

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Three-Dimensional Telomere Analysis Using Teloview® Technology Predicts the Response of Classic Hodgkin's Lymphoma Patients to First Line Therapy at Point of Diagnosis

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

Apoptotic Blocks in Primary Non-Hodgkin B-Cell Lymphomas Identified By BH3 Profiling

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP

Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets

Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing

BCL2 Is Highly Mutated In Diffuse Large B-Cell Lymphoma

Mutations In MLL2 and MEF2B Genes In Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.

FAS Mutations in Follicular Lymphoma Are Rare but Associated with Aggressive Clinical Behavior.

Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner

Paraffin-Based 6-Gene Model Predicts Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.

Insights into Disease Evolution of Transformed Follicular Lymphoma Derived from Cytogenetics.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only